Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
O
382150
vs
K
KOSPI 200
Over the past 12 months, OnCoCross Co Ltd has underperformed KOSPI 200, delivering a return of +0% compared to KOSPI 200's +119% growth.
Stocks Performance
382150 vs KOSPI 200
Performance Gap
382150 vs KOSPI 200
Performance By Year
382150 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OnCoCross Co Ltd
Glance View
Oncocross Co., Ltd. engages in conducting joint research on new drugs with several domestic and foreign pharmaceutical companies. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-12-18. The firm mainly develops artificial intelligence (AI) new drug development platform based on its original technology which analyzing changes in gene expression data (Transcriptome) due to drug administration or disease occurrence and using AI to match the optimal disease and treatment. The firm mainly develops treatments for rare diseases, cancer, dementia and other intractable diseases.